StemCell Therapy

Millions of people around the world live with diabetes or know someone living with diabetes. Regardless of the type of diabetes, diabetes isnt yet a curable disease. However, it is a very treatable disease, and no matter how frightening, annoying, and frustrating it can be, people with diabetes can live long, healthy, and happy lives.Our goal is to provide you the information, tools and resources to help make that happen.

This is the place to begin your education about diabetes.

This section of our site provides basic overviews of the major issues surrounding diabetes, with plenty of links to more in-depth information if you need it.

Take our type 2 diabetes risk test for a quick assessment of your risk.

There is no way to predict your chances of getting type 1 diabetes, but you can familiarize yourself with its symptoms.

Type 1 diabetes is usually diagnosed in children and young adults, and was previously known as juvenile diabetes.

Expecting? Learn why women who have never had diabetes may be at risk during pregnancy.

The numbers associated with diabetes make a strong case for devoting more resources to finding a cure.

Clear up some common misunderstandings about what causes diabetes, the effects of diabetes, and how diabetes can be managed.

Become familiar with terms commonly used when discussing diabetes.

Pulitzer prize winning photographer Jay Dickman, volunteered his time and talent to photograph three individuals that are living with diabetes to share their up close and personal daily lives.

These well-known men and women have joined the Association's "Celebrity Cabinet" to help stop diabetes.

See original here:
Diabetes Basics

Our Integrative Medicine Physician

Steven Rosenzweig, MD graduated from the University of Pennsylvania School of Medicine in 1986 and completed his residency training in Emergency Medicine at Jefferson University Hospital in 1989. He was a full-time Jefferson physician until 2007. During that time he served as the Founding Medical and Academic Director of the Thomas Jefferson University Center of Integrative Medicine, which opened its doors in 1998. In 2007 he established his independent, private practice in Integrative Medicine and also joined the teaching faculty of Drexel University College of Medicine.

Dr. Rosenzweig is Board Certified in Emergency Medicine and Palliative Medicine. He extended his medical training through the study of Anthroposophical Medicine, a European-based system of Integrative Medicine. He participated in professional training under the direction of Jon Kabat-Zinn, PhD, founder of the Stress Reduction Clinic at the University of Massachusetts Medical Center (UMMC), and has completed the Teacher Development Intensive in Mindfulness-Based Stress Reduction offered at the Stress Reduction Clinic at UMMC. He also completed Professional Certification Training in Interactive Guided Imagerysm through the Academy for Guided Imagery.

Dr. Rosenzweig is Clinical Associate Professor at Drexel University College of Medicine where he is Director of the Program in Medical Humanism and Professional Values in the Office of Educational Affairs. He directs courses in Bioethics, Community Service Learning and Professionalism. He teaches mindfulness and Integrative Medicine, and has been developing mind-body projects as part of the community service curriculum. He is also an Adjunct Associate Professor at Jefferson Medical College where he currently lectures on botanical medicine and racial disparities in healthcare. Dr.Rosenzweig is also a member of the medical staff of Hahnemann University Hospital and Abington Memorial Hospital.

Visit link:
Integrative Medicine in Philadelphia Healing Arts Center ...

At Penn Medicines Abramson Cancer Center, we are proud to offer integrative oncology services to supplement traditional cancer treatments such as chemotherapy, surgery and radiation therapy. The Abramson Cancer Centers wide range of integrative oncology options are designed to help you minimize or reduce side effects of cancer and cancer treatment, and promote your healing and recovery, and improve your overall sense of well-being.

For more information, read the Integrative Oncology frequently asked questions.

Services include:

Penns Integrative Oncology patient navigator connects patients and families to integrative services at Penn and in the community. She can help schedule an appointment or provide insight into the different therapies offered.

Laura Galindez, MSW, LSWIntegrative Oncology Patient Navigator215-360-0580 or laura.galindez@uphs.upenn.edu

Research being conducted at Penn Medicine tests the effects and mechanisms of promising health behaviors and integrative therapeutic approaches for symptom management and wellness promotion in cancer. Researchers at Penn are exploring ways to best incorporate integrative therapies safely and effectively into the conventional medical therapies to create patient-centered care for optimal health and healing.

More here:
Integrative Oncology Services Abramson Cancer Center

This article is about a type of pregnancy. For other uses of the word "surrogacy", see Surrogate. Legal status of surrogacy in the world:

Both gainful and altruistic forms are legal

No legal regulation

Only altruistic is legal

Allowed between relatives up to second degree of consanguinity

Banned

Unregulated/uncertain situation

Surrogacy is an arrangement, often supported by a legal agreement, whereby a woman agrees to become pregnant, carry the pregnancy to due term, and give birth to a child or children, all of this for another person or persons, who are or will ultimately become the parent(s) of the child or children.

People may seek a surrogacy arrangement when pregnancy is medically impossible, when pregnancy risks present an unacceptable danger to the mother's health, or when a man alone or a male couple wishes to have a child. In these arrangements, monetary compensation may or may not be involved. Receiving money for the arrangement is considered commercial surrogacy; receiving no compensation beyond reimbursement of reasonable expenses is altruistic.[1] The legality and cost of surrogacy varies widely between jurisdictions, sometimes resulting in problematic interstate or international surrogacy arrangements.

Laws of some countries restrict or regulate surrogacy and its consequences. Those wanting to seek a surrogacy arrangement who, however, live where it is banned may travel to a jurisdiction that permits it. (See surrogacy laws by country and fertility tourism.)

The fertilisation of the egg may take place in a number of ways, each of which has implications for the genetic relationship of the resulting child with the surrogate and the future parents. There are two main types of surrogacy: gestational surrogacy and traditional surrogacy. In the United States, gestational surrogacy is more common than traditional surrogacy and is considered less legally complex.[2]

Traditional surrogacy (also known as partial, genetic, natural or straight surrogacy[3]) involves natural[4] or artificial insemination of a surrogate. If the intended father's sperm is used in the insemination, then the resulting child is genetically related to the intended father and genetically related to the surrogate. If donor sperm is used, the resulting child is not genetically related to either intended parent but is genetically related to the surrogate.

In some cases, an insemination may be performed privately by the parties without the intervention of a doctor or physician. In some jurisdictions, the 'commissioning parents' using donor sperms need to go through an adoption process in order to have legal rights in respect to the resulting child. Many fertility centers which provide for surrogacy assist the parties through the process.

Gestational surrogacy (also known as host or full surrogacy[3]) was first achieved in April 1986.[5] It takes place when an embryo created by in vitro fertilization (IVF) technology is implanted in a surrogate, sometimes called a gestational carrier. Gestational surrogacy may take a number of forms, but in each form the resulting child is genetically unrelated to the surrogate:

In places where surrogacy is legal, couples may enlist the help of a third party agency to oversee the process of finding a surrogate, entering into a contract with her and recommend fertility centers for insemination, generally via IVF. These agencies can help make sure that surrogates are screened with psychological evaluations and other medical tests so as to ensure the best chance of healthy deliveries. They also usually facilitate all legal matters concerning the two parties (intended parents and surrogate).

Having another woman bear a child for a couple to raise, usually with the male half of the couple as the genetic father, is referred to in antiquity. Babylonian law and custom allowed this practice, and an infertile woman could use the practice to avoid a divorce, which would otherwise be inevitable.[6][7]

Many developments in medicine, social customs, and legal proceedings worldwide paved the way for modern surrogacy:[8]

Surrogacy has the potential for various kinds of clash between surrogate mothers and intended parents. For instance, the intended parents of the fetus may ask for an abortion when complications arise and the surrogate mother may oppose the abortion.[10][11]

Surrogacy is controversial around the world, raising difficult moral, social and legal issues. As a result, the legal situation varies considerably. Many countries do not have laws which specifically deal with surrogacy. Some countries ban surrogacy outright, while others ban commercial surrogacy but allow altruistic surrogacy (in which the surrogate is not financially compensated). Some countries allow commercial surrogacy, with few restrictions. Some jurisdictions extend a ban on surrogacy to international surrogacy. In some jurisdictions rules applicable to adoptions apply and in others the practice is unregulated.

The US, Ukraine, Russia and Georgia have the most liberal laws in the world, allowing commercial surrogacy, including for foreigners.[12] Several Asian countries used to have liberal laws, but the practice has since been restricted. In 2015, Thailand banned commercial surrogacy, and restricted altruistic surrogacy to Thai couples.[13] In 2016, Cambodia also banned commercial surrogacy.[14] Nepal, Mexico, and India, have also recently banned foreign commercial surrogacy.[15] Surrogacy is legal and common in Iran; and monetary remuneration is practiced and allowed by religious authorities.[16][17]

Laws dealing with surrogacy must deal with:

Although laws differ widely from one jurisdiction to another, some generalizations are possible:

The historical legal assumption has been that the woman giving birth to a child is that child's legal mother, and the only way for another woman to be recognized as the mother is through adoption (usually requiring the birth mother's formal abandonment of parental rights).

Even in jurisdictions that do not recognize surrogacy arrangements, if the genetic parents and the birth mother proceed without any intervention from the government and have no changes of heart along the way, they will likely be able to achieve the effects of surrogacy by having the surrogate mother give birth and then give the child up for private adoption to the intended parents.

If the jurisdiction specifically prohibits surrogacy, however, and authorities find out about the arrangement, there may be financial and legal consequences for the parties involved. One jurisdiction (Quebec) prevented the genetic mother's adoption of the child even though that left the child with no legal mother.[18]

Some jurisdictions specifically prohibit only commercial and not altruistic surrogacy. Even jurisdictions that do not prohibit surrogacy may rule that surrogacy contracts (commercial, altruistic, or both) are void. If the contract is either prohibited or void, then there is no recourse if one party to the agreement has a change of heart: if a surrogate changes her mind and decides to keep the child, the intended mother has no claim to the child even if it is her genetic offspring, and the couple cannot get back any money they may have paid or reimbursed to the surrogate; if the intended parents change their mind and do not want the child after all, the surrogate cannot get any reimbursement for expenses, or any promised payment, and she will be left with legal custody of the child.

Jurisdictions that permit surrogacy sometimes offer a way for the intended mother, especially if she is also the genetic mother, to be recognized as the legal mother without going through the process of abandonment and adoption. Often this is via a birth order[19] in which a court rules on the legal parentage of a child. These orders usually require the consent of all parties involved, sometimes including even the husband of a married gestational surrogate. Most jurisdictions provide for only a post-birth order, often out of an unwillingness to force the surrogate mother to give up parental rights if she changes her mind after the birth.

A few jurisdictions do provide for pre-birth orders, generally in only those cases when the surrogate mother is not genetically related to the expected child. Some jurisdictions impose other requirements in order to issue birth orders: for example, that the intended parents be heterosexual and married to one another. Jurisdictions that provide for pre-birth orders are also more likely to provide for some kind of enforcement of surrogacy contracts.

The citizenship and legal status of the children resulting from surrogacy arrangements can be problematic. The Hague Conference Permanent Bureau identified the question of citizenship of these children as a "pressing problem" in the Permanent Bureau 2014 Study (Hague Conference PermanentBureau, 2014a: 84-94).[20][21] According to U.S. Department of State, Bureau of Consular Affairs, for the child to be a U.S. citizen one or both of the child's genetic parents must be a U.S. citizen. In other words, the only way for the child to acquire U.S. citizenship automatically at birth is if he/she is the biological son or daughter of a U.S. citizen. Further, in some countries, the child will not be a citizen of the country in which he/she is born because the surrogate mother is not legally the parent of said child. This could result in a child being born without citizenship.[22]

Ethical issues that have been raised with regards to surrogacy include the following:[23]

Different religions take different approaches to surrogacy, often related to their stances on assisted reproductive technology in general.

Paragraph 2376 of the Catechism of the Catholic Church states that: "Techniques that entail the dissociation of husband and wife, by the intrusion of a person other than the couple (donation of sperm or ovum, surrogate uterus), are gravely immoral."[24]

Jewish legal scholars debate this issue. Some contend that parenthood is determined by the woman giving birth while others opt to consider the genetic parents the legal parents.[25][26] Some Jewish religious establishments have accepted surrogacy only if it is full gestational surrogacy with both intended parents' gametes included and fertilization done via IVF.[27]

Hindu scholars have not debated the issue. TC Anand Kumar argues that here is no conflict between Hinduism and assisted reproduction.[28].

Jain scholars have not debated the issue. In the Shvetambara tradition of Jainism, the embryo of Lord Mahavira was transferred from a Brahmin woman Devananada to the womb of Trishala, the queen of Kshatriya ruler Siddharth, by a divinity named Harinegameshin.[29] The account is not present in the Digambara Jain texts.

A study by the Family and Child Psychology Research Centre at City University London in 2002 concluded that surrogate mothers rarely had difficulty relinquishing rights to a surrogate child and that the intended mothers showed greater warmth to the child than mothers conceiving naturally.[30][31][32]

Anthropological studies of surrogates have shown that surrogates engage in various distancing techniques throughout the surrogate pregnancy so as to ensure that they do not become emotionally attached to the baby.[33][34] Many surrogates intentionally try to foster the development of emotional attachment between the intended mother and the surrogate child.[35]

Surrogates who work with an agency are generally counseled by the agency to become emotionally detached from the fetus prior to giving birth.[36]

Some surrogates describe feeling empowered by the experience.[34][37]

Although surrogate mothers generally report being satisfied with their experience as surrogates, there are cases in which they are not. Unmet expectations are associated with dissatisfaction. Some women did not feel a certain level of closeness with the couple and others did not feel respected by the couple.[38]

Some women experience emotional distress as a surrogate mother. There may be a lack of access to therapy and emotional support through the surrogate process.[38]

Some surrogate mothers have reactions that include depression when surrendering the child, grief, and even refusal to release the child.[39]

A 2011 study from the Centre for Family Research at the University of Cambridge found that surrogacy does not have a negative impact on the surrogate's own children.[40]

A study has followed a cohort of 32 surrogacy, 32 egg donation, and 54 natural conception families through to age seven, reporting the impact of surrogacy on the families and children at ages one,[32] two,[41] and seven.[42] At age one, parents through surrogacy showed greater psychological well-being and adaptation to parenthood than those who conceived naturally; there were no differences in infant temperament. At age two, parents through surrogacy showed more positive motherchild relationships and less parenting stress on the part of fathers than their natural conception counterparts; there were no differences in child development between these two groups. At age seven, the surrogacy and egg donation families showed less positive motherchild interaction than the natural conception families, but there were no differences in maternal positive or negative attitudes or child adjustment. The researchers concluded that the surrogacy families continued to function well.

In Australia, all jurisdictions except the Northern Territory allow altruistic surrogacy, but commercial surrogacy is a criminal offense. The Northern Territory has no legislation governing surrogacy.[43] In New South Wales, Queensland and the Australian Capital Territory it is an offence to enter into international commercial surrogacy arrangements, with potential penalties extending to imprisonment for up to one year in Australian Capital Territory, up to two years in New South Wales and up to three years in Queensland.

Altruistic surrogacy was legalized in Belgium.

The Assisted Human Reproduction Act (AHRC) permits only altruistic surrogacy: surrogate mothers may be reimbursed for approved expenses but payment of any other consideration or fee is illegal.[44]

Altruistic surrogacy was legalized in Denmark.

Gainful surrogacy is made illegal by the Charter of Fundamental Rights, whose Article 3 states that "making the human body and its parts as such a source of financial gain" is prohibited.[45]

Surrogacy has been illegal since law amendment in 2007. Children born abroad for Finnish parents by surrogacy will not be entitled to get Finnish Citizenship.

All surrogacy arrangements (both commercial and altruistic) are illegal. German party FDP wants to allow altruistic surrogacy.[46]

Law 3305/2005 (Enforcement of Medically Assisted Reproduction) makes surrogacy in Greece fully legal. Greece is only one of a handful of countries in the world to give legal protection to intended parents. Intended parents must meet certain qualifications and will go before a family judge before entering into a surrogacy contract. As long as they meet the qualifications, the court appearance is procedural and their application will be granted. At present, intended parents must be in a heterosexual partnership or be a single female. Females must be able to prove there is a medical indication they cannot carry and be no older than 50 at the time of the contract. As in all jurisdictions, surrogates must pass medical and psychological tests so they can prove to the court that they are medically and mentally fit. Greece is the only country in Europe, and one of only countries in the world, where the surrogate then has no rights over the child. The intended parents become the legal parents from conception, and there is no mention of the surrogate mother anywhere on hospital or birth documents. The intended parent(s) are listed as the parents. This even applies if an egg or sperm donor is used by one of the partners. As a result of the Schengen Treaty, intended parents from throughout Europe can freely travel home as soon as the baby is born and deal with citizenship issues at that time, as opposed to applying at their own embassy in Greece. Before 2014 (pursuant to art. 8 of Law 3089/2002), the surrogate mother and the commissioning parents were required to be Greek citizens or permanent residents. However, in July 2014, L. 4272/2014 extended legal surrogacy to applicants or surrogate mothers who have either permanent or temporary residence in Greece.

There is no law in Ireland governing surrogacy. In 2005 a Government appointed Commission published a comprehensive report on Assisted Human Reproduction, which made many recommendations on the broader area of assisted human reproduction. In relation to surrogacy it recommended that the commissioning couple would under Irish law be regarded as the parents of the child. Despite the publication there has been no legislation published, and the area essentially remains unregulated. Due to mounting pressure from Irish citizens going abroad to have children through surrogacy, the Minister for Justice, Equality and Defence published guidelines for them on 21 February 2012.[47]

Altruistic surrogacy was legalized in the Netherlands.

Altruistic surrogacy is legal, but commercial surrogacy is not.

Gestational surrogacy is currently practiced in Nigeria by a few IVF clinics, under practice guidelines from the Association of Fertility and Reproductive Health of Nigeria. An assisted reproduction technology regulation being considered by the Senate permits surrogacy and allows payments for transport and other expenses.[48]

In 2016, gestational surrogacy was legalized in Portugal. Discussions on the adoption of this law lasted more than 3 years. The first version of the law was adopted May 13, 2016, but the president vetoed it. He demanded that the law specify the rights and obligations of all participants.

Portugal allows surrogacy only for those couples in which the woman cannot carry and give birth to a child for medical reasons. Only altruistic surrogacy is permitted. A written agreement must be issued between the surrogate mother and the genetic parents. The rights and obligations of the parties as well as their actions in cases of force majeure should be included in it. After the birth, parental rights over the child belong to the genetic parents.

Traditional surrogacy (in which the surrogate is a genetic parent) is illegal in Portugal.

Heterosexual and lesbian couples can become parents via surrogacy in Portugal under the 2016 law. Male homosexual couples and single men and women of any sexual orientation have not yet been included, but they are not addressed specifically. A revision to include them is on the current manifestos of the Left Bloc, PeopleAnimalsNature, and The Greens). The right-wing party CDS-PP and the Portuguese Communist Party are opposed.

The South Africa Children's Act of 2005 (which came fully into force in 2010) enabled the "commissioning parents" and the surrogate to have their surrogacy agreement validated by the High Court even before fertilization. This allows the commissioning parents to be recognized as legal parents from the outset of the process and helps prevent uncertainty. If the surrogate mother is the genetic mother, however, she has until 60 days after the birth of the child to change her mind. The law permits single people and gay couples to be commissioning parents.[49] However, only those domiciled in South Africa benefit from the protection of the law, no non-validated agreements will be enforced, and agreements must be altruistic rather than commercial. If there is only one commissioning parent, s/he must be genetically related to the child. If there are two, they must both be genetically related to the child unless that is physically impossible due to infertility or sex (as in the case of a same sex couple). The commissioning parent or parents must be physically unable to birth a child independently. The surrogate mother must have had at least one pregnancy and viable delivery and have at least one living child. The surrogate mother has the right to unilaterally terminate the pregnancy, but she must consult with and inform the commissioning parents, and if she is terminating for a non-medical reason, may be obliged to refund any medical reimbursements she had received.[50]

The Spanish Human Assisted Reproductive Technologies Act of 2006 made surrocagy arrangements, either commercial or altruistic, null and void. Thus, the intended mother won't be recognised as such; the woman who gives birth will be the legal mother. On the other hand, the biological father will have an action to claim his paternity, by acknowledgment or judicial claim. Despite the aforementioned, surrogacy arrangements made abroad are recognised by Spanish authorities in some circumstances.

In June 2017, the political party Ciudadanos registered a bill in the Congress of the Deputies to legalise altruistic surrogacy. No other political party supports this idea.

Altruistic surrogacy remains illegal in Sweden.

Commercial surrogacy arrangements are not legal in the United Kingdom. Such arrangements were prohibited by the Surrogacy Arrangements Act 1985.[51] Whilst it is illegal in the UK to pay more than expenses for a surrogacy, the relationship is recognised under section 30 of the Human Fertilisation and Embryology Act 1990. Regardless of contractual or financial consideration for expenses, surrogacy arrangements are not legally enforceable so a surrogate mother maintains the legal right of determination for the child, even if they are genetically unrelated. Unless a parental order or adoption order is made, the surrogate mother remains the legal mother of the child.

Surrogacy and its attendant legal issues fall under state jurisdiction and the legal situation for surrogacy varies greatly from state to state. Some states have written legislation, while others have developed common law regimes for dealing with surrogacy issues. Some states facilitate surrogacy and surrogacy contracts, others simply refuse to enforce them, and some penalize commercial surrogacy. Surrogacy-friendly states tend to enforce both commercial and altruistic surrogacy contracts and facilitate straightforward ways for the intended parents to be recognized as the child's legal parents. Some relatively surrogacy-friendly states offer support only for married heterosexual couples. Generally, only gestational surrogacy is supported and traditional surrogacy finds little to no legal support.

States generally considered to be surrogacy friendly include California,[52] Oregon,[53] Illinois,[54] Arkansas,[55] Maryland,[56] New Hampshire,[57] New Jersey (effective from 1/1/2019) and Washington State (eff. 1/1/2019).[58][59]

For legal purposes, key factors are where the contract is completed, where the surrogate mother resides, and where the birth takes place. Therefore, individuals living in a non-friendly state can still benefit from the policies of surrogacy friendly states by working with a surrogate who lives and will give birth in a friendly state.

Fertility tourism for surrogacy is driven by legal regulations in the home country or lower price abroad.

India is a main destination for surrogacy. Indian surrogates have been increasingly popular with intended parents in industrialized nations because of the relatively low cost. Clinics charge patients between $10,000 and $28,000 for the complete package, including fertilization, the surrogate's fee, and delivery of the baby at a hospital. Including the costs of flight tickets, medical procedures and hotels, it comes to roughly a third of the price compared with going through the procedure in the UK.[60]

Surrogacy in India is of low cost and the laws are flexible. In 2008, the Supreme Court of India in the Manji's case (Japanese Baby) has held that commercial surrogacy is permitted in India. That has increased the international confidence in surrogacy arrangements in India. As of 2014, however, surrogacy by homosexual couples and single parents was banned[citation needed].

There is an upcoming Assisted Reproductive Technology Bill, aimed at regulating the surrogacy business. It may increase parent confidence in clinics by eliminating dubious practitioners, and in this way stimulate the practice.[60]

Liberal legislation makes Russia attractive for those looking for techniques not available in their countries. Intended parents come there for oocyte donation, because of advanced age or marital status (single women and single men), and when surrogacy is considered. Commercial gestational surrogacy is legal in Russia, being available to almost all adults willing to be parents.[61] Foreigners have the same rights to assisted reproduction as Russian citizens. Within three days after the birth, the commissioning parents obtain a Russian birth certificate with both their names on it. Genetic relation to the child (in case of donation) is not a factor.[62]On August 4, 2010, a Moscow court ruled that a single man who applied for gestational surrogacy (using donor eggs) could be listed on the birth certificate as the only parent of his son.[63]

Surrogacy is legal in Ukraine. Only healthy women who have had children before can become surrogates. Surrogates in Ukraine have no parental rights over the child, as stated on Article 123 of the Family Code of Ukraine. Thus, a surrogate cannot refuse to hand the baby over if she changes her mind after birth. Only married couples can legally go through gestational surrogacy in Ukraine.

People come to the US for surrogacy procedures for the high quality of medical technology and care, as well as the high level of legal protections afforded through some US state courts to surrogacy contracts as compared to many other countries. Single men or male couples who face restrictions using IVF and surrogacy procedures in their home countries may travel to US states with favorable legal climates. The United States is occasionally sought as a location for surrogate mothers by couples seeking a green card in the U.S., since the resulting child can get birthright citizenship in the United States and can thereby apply for green cards for the parents when the child turns 21 years of age.[64]

Read more:
Surrogacy - Wikipedia

The following services are available to patients of Integrative Medicine of New Jersey:

Aesthetic Services:

Gemini Laser Laser Skin Rejuvenation & Pigmentation Treatment

The Gemini Laser can selectively treat a variety of skin problems with minimal or no disruption to the surrounding normal skin:

The Gemini Laser cannot treat moles or skin cancers.

It is most commonly used on the face, neck, chest, back, and hands.

The first step is simply contacting us for your initial laser skin rejuvenation consultation. We will discuss with you what is a realistic and achievable outcome, and what to expect from your laser treatment.

Homeopathic Facial Mesotherapy

As we age, our skin loses vital nutrients as a result of sun exposure, hormonal changes, poor diet and poor circulation. Homeopathic facial mesotherapy, also known as anti-aging mesotherapy, uses intra-dermal injections of a nutritive and moisturizing solution to improve brightness, skin hydration and tonus, and also smooth out superficial wrinkles. This technique delivers the required nutrients like those naturally found in the body vitamins, amino acids, co-enzymes, collagen and antioxidants to particular areas of the skin. Concentration of these molecules in homeopathic medicines aims to rejuvenate the cells, making them more active, and thereby stimulating the production of collagen and elastin without the involvement of toxins. With this revolutionary face treatment you will experience: restoration of skin elasticity, improvement of skin tone, firming and tightening of the skin and a reduction of visible wrinkles. Integrative Medicine of New Jersey uses only safe, natural, and effective FDA approved homeopathic solutions from GUNA.

Platelet-Rich Plasma Therapy (PRP) Stem Rejuvenation

Platelet-rich plasma (PRP) therapy, also known as Stem Rejuvenation, involves injection of the patients own platelets and fibrin for the cosmetic treatment of wrinkles or scars in the face, hands, and neck. It is not invasive, takes about one hour for each treatment, and continues to show improvements for up to 18 months as stem cells continually work to rejuvenate the skin creating more collagen and a beautiful shine. Cost of the procedure is generally similar to that of fillers and may range from $900 to $1,200 per treatment.Platelets play a role in stopping bleeding and in repairing damaged blood vessels and cells in the body. Platelets also contain substances called growth factors that activate and rejuvenate cells in our body. PRP uses the patients natural biology to address skin defects and volume loss, triggering production of new cells and collagen formation.

This cutting-edge rejuvenation is a quick one hour procedure. After 50ml of blood is drawn from the patient, it is spun down in a centrifuge for 6 minutes at a precalculated speed to retrieve the most viable fibrin and platelets. After centrifugation, the platelet and fibrin component of the blood (the top layer) is extracted and reinjected into the area of concern.For those looking to delay the aging process, Stem Rejuvenation is a new facial rejuvenation procedure that promises to reverse the aging process and reduce the appearance of wrinkles, lines and blemishes.Stem Rejuvenation is a natural product that utilizes regenerated cells and allows individuals to appear younger within a short period of time. The targeted Stem Rejuvenation audience is people who are looking for a younger rejuvenated look. The procedure can be done in your doctors office with minimal pain. The most common side effects include, but are not limited to, temporary injection site reactions such as redness, pain/tenderness, swelling, lumps/bumps, bruising and some patients experience headaches. These side effects usually dont last past 48 hours.

Diagnostic Services:

Allergy Testing

In allergic people, an excess of a certain antibody called IgE is often produced. These IgE antibodies react and release inflammatory chemicals when they contact allergens (e.g. pollens, dust mites, mold spores, animal dander, foods, drugs, dyes) and then allergy symptoms are produced.

The measurement of IgE antibodies is the key to effective allergy diagnosis and treatment. The doctor may choose to test the patient using skin tests, a blood test, or both. In years past, the only method of testing for allergies was by scratching or injection a liquid extract of the suspected offending substance(s) into the skin and observing it for development of a welt. Now it is possible to use a blood test to measure a patients IgE antibodies to a wide variety of allergens. A small sample of blood can be analyzed in the laboratory for a safe and accurate diagnosis. Skin tests and the blood test are often used to confirm one another. Both tests provide the doctor with information to help her decide how your allergies should be treated. Each patients treatment is customized and tailored to the patients lifestyle.

ANSAR (Autonomic Nervous System Monitoring)

The autonomic nervous system (ANS) is the part of your nervous system which functions to sustain life by helping to control your heart, lungs, digestive system, blood pressure, immune system, certain reflexes, fluid balance, pupil diameter, sleep, sweating, hormones, kidney, and sexual function. There are two branches, or parts within your autonomic nervous system; the sympathetic branch and the parasympathetic branch. Generally, the sympathetic branch is more in control when you are stressed, nervous, or excited, while the parasympathetic branch is more in control when you are relaxing, sleeping, or recovering from an illness or injury. A balance between the two branches is essential for good health. Most illnesses and injuries can cause (or result from) an imbalance between these two branches.

Autonomic nervous system monitoring is a fast, non-invasive, and simple way to provide your doctor with information to help determine how healthy you are. Everyone from newborns to older adults can and should have their ANS monitored. ANS monitoring records your ECG and respiratory activity. Blood pressure readings are also taken. Your ECG and respiratory activity are analyzed by the ANS monitor to determine how your ANS is controlling your heart, lungs, and other vital organs of your body. Your doctor then interprets your Parasympathetic and Sympathetic (P&S) results produced by the ANS Monitor. Too much or too little P&S activity is not healthy. This information can help your doctor adjust your balance for better health.

Cardiac Health Screen Holter Monitor

Holter monitoring (24h) refers to a 24-hour, continuous test to record your heart rate and rhythm. This device has electrodes and electrical leads exactly like a regular electrocardiogram. A patient wears the Holter monitor for 12 to 48 hours as they go about their normal daily routines. This testing is ordered when your doctor needs more information about the functioning of your heart than a routine electrocardiogram (EKG) can give her.

Why do people wear Holter monitors?

Regular electrocardiograms (ECGs or EKGs) let your doctor look at your hearts activity at one point in time during your ECG test. But abnormal heart rhythms and cardiac symptoms may come and go. Thats why your doctor may want to evaluate your heartbeat over time while you go about your normal activities. You may be asked to wear a Holter monitor if you have fast, slow or irregular heartbeats called arrhythmias.

Wearing the monitor may tell your doctor:

Micronutrient Testing

Vitamin, mineral and antioxidant deficiencies have been shown to suppress the function of the immune system which can contribute to degenerative processes such as arthritis, cancer, cardiovascular disease and diabetes. You may be deficient in some vitamins, minerals, antioxidants, and/or other essential micronutrients and not even know it.

Test results do not typically measure if the nutrient is properly functioning within the body. Our office uses testing that measures the function of selected vitamins, minerals, antioxidants and other essential micronutrients within your white blood cells. Analysis can reveal a persons functional nutrient status over a much longer time period than conventional serum testing. Get your micronutrient tests today. The test results provide the information needed to create your personalized supplementation and repletion program.

Neurotransmitter Testing

The following symptoms can be triggered by nervous system imbalances: low mood, anxiousness, fatigue, difficulty falling asleep, difficulty staying asleep, trouble focusing, poor memory, weight gain.

A simple urine test can identify which neurotransmitter(s) may be playing a role in your health concerns. Neurotransmitter test results are like neural fingerprints, each one is unique and provides your doctor with a wealth of information. Once your doctor knows which neurotransmitters are elevated and which are low, she can help you select the therapies, lifestyle adjustments, and nutritional support products you need to restore balance.

Additional Therapeutic Services:

IV Therapy:

Vitamin C DripMineral DripImmune Tune-UpGlutathione IV PushChelation EDTA

Vitamin IV

Uses for Vitamin IV therapy:

Asthma attacksAdrenal Stress InsufficiencyMalabsorptionAcute Bacterial and Viral IllnessesAllergic DisordersPMSHeadachesImmune System BoosterRemoval of Heavy MetalsIncreases Energy Level

Call Integrative Medicine of New Jersey at (973) 736-5300 for more information and to schedule your appointment.

See the rest here:
Additional Services | Integrative Medicine of New Jersey

Stem Cell Intro

Ordinary cells in your body replicate to make new cells of the same type blood cells make more blood cells, skin cells make more skins cells and so on. However, there is another type of cell, called a stem cell.

Stem cells are able to repair or replace damaged tissue. This is why scientists and doctors are so excited about the growing role of stem cells to treat disease, injury, and the deterioration of tissue due to aging. Amazingly, after our birth and into adulthood, we keep a store of these stem cells in certain parts of our body.

Different types of stem cells exist in different body tissues, and in varying concentrations. One of the most well-understood and widely researched types of stem cells is the mesenchymal stem cell.

Mesenchymal stem cells can form tissues such as bone, nerve, muscle and blood vessels. They also help body tissue to repair itself, and they play an important role in healing by suppressing inflammation.

Though located in a number of places in the body, mesenchymal stem cells can be found in especially high concentrations in the healthy dental pulp of teeth.

Over time, even stem cells succumb to the environmental insults that age all of our cells. Freezing cells in a youthful state preserves their future ability to generate replacement tissue and heal the body.

All of these attributes make stem cells the cornerstone of the emerging field of treatments and therapies called Regenerative Medicine.

Mesenchymal stem cells have already proven to be a powerful and potent platform for developing treatments. As you are reading this, scientists are studying the role of these amazing cells in treating conditions such as type 1 diabetes, spinal cord injury, stroke, myocardial infarction (heart attack), corneal damage and neurological diseases like Parkinsons, to name just a few.

Hundreds of clinical trials are underway, demonstrating the use of mesenchymal stem cells to treat diseases, to heal injuries, and to grow replacement tissues like bone, nerve, muscle and blood vessels. In fact, mesenchymal stem cells are currently being tested clinically to treat autoimmune diseases like Crohns and GVHD as well as in regenerative applications like bone and cartilage repair and cardiac muscle repair after myocardial infarction.

This exploding field of research, called Regenerative Medicine, holds the promise that your child, utilizing a toolkit of their own stem cells harvested and stored early on, will live a life of unprecedented wellness. Regenerative medical therapies could become common treatments used alongside more traditional ones.

Imagine a future where serious conditions like type 1 diabetes are treated with a combination of drugs and regenerative medicine. Imagine skin and bone grafts created from the patients own cells. Imagine treating age-related conditions like arthritis, dementia, and Alzheimers using cells from the patients teeth that were banked when they were young.

Want to dig deeper into emerging therapies using mesenchymal stem cells?

To learn more, visit http://www.store-a-tooth.com or call (877) 867-5753 to speak with a client educator.

View post:
Dental Stem Cells in Chicago, IL | Harold Krinsky, DDS

Neurogenesis is the process by which nervous system cells, known as neurons, are produced by neural stem cells (NSC)s, and it occurs in all species of animals except the porifera (sponges) and placozoans.[1] Types of NSCs include neuroepithelial cells (NECs), radial glial cells (RGCs), basal progenitors (BPs), intermediate neuronal precursors (INP)s, subventricular zone astrocytes, and subgranular zone radial astrocytes, among others.[2] Neurogenesis is most active during embryonic development, and is responsible for producing all the various types of neurons of the organism, but continues throughout adult life in a variety of organisms.[3] Once born, neurons do not divide (see mitosis), and many will live the lifetime of the animal.[4]

During embryonic development, the mammalian central nervous system (CNS; brain and spinal cord) is derived from the neural tube, which contains NSCs that will later generate neurons.[5] However, neurogenesis doesn't begin until a sufficient population of NSCs has been achieved. These early stem cells are called neuroepithelial cells (NEC)s, but soon take on a highly elongated radial morphology and are then known as radial glial cells (RGC)s.[6] RGCs are the primary stem cells of the mammalian CNS, and reside in the embryonic ventricular zone, which lies adjacent to the central fluid-filled cavity (ventricular system) of the neural tube.[7][8] Following RGC proliferation, neurogenesis involves a final cell division of the parent RGC, which produces one of two possible outcomes. First, this may generate a subclass of neuronal progenitors called intermediate neuronal precursors (INP)s, which will divide one or more additional times to produce neurons. Alternatively, daughter neurons may be produced directly. Neurons do not immediately form neural circuits through the growth of axons and dendrites. Instead, newborn neurons must first migrate long distances to their final destinations, maturing and finally generating neural circuitry. For example, neurons born in the ventricular zone migrate radially to the cortical plate, which is where neurons accumulate to form the cerebral cortex.[9][10] Thus, the generation of neurons occurs in a specific tissue compartment or 'neurogenic niche' occupied by their parent stem cells.

The rate of neurogenesis and the type of neuron generated (broadly, excitatory or inhibitory) are principally determined by molecular and genetic factors. These factors notably include the Notch signaling pathway, and many genes have been linked to Notch pathway regulation.[11][12] The genes and mechanisms involved in regulating neurogenesis are the subject of intensive research in academic, pharmaceutical, and government settings worldwide.

The amount of time required to generate all the neurons of the CNS varies widely across mammals, and brain neurogenesis is not always complete by the time of birth.[13] For example, mice undergo cortical neurogenesis from about embryonic day (post-conceptional day) (E)11 to E17, and are born at about E19.5.[14] Ferrets are born at E42, although their period of cortical neurogenesis does not end until a few days after birth.[15] In contrast, neurogenesis in humans generally begins around gestational week (GW) 10 and ends around GW 25 with birth about GW 38-40.[16]

Adult neurogenesis has been shown to occur at low levels compared with development, and in only two regions of the brain: the adult subventricular zone (SVZ) of the lateral ventricles, and the dentate gyrus of the hippocampus.[17][18][19]

In many mammals, including for example rodents, the olfactory bulb is a brain region containing cells that detect smell, featuring integration of adult-born neurons, which migrate from the SVZ of the striatum to the olfactory bulb through the rostral migratory stream (RMS).[20][21] The migrating neuroblasts in the olfactory bulb become interneurons that help the brain communicate with these sensory cells. The majority of those interneurons are inhibitory granule cells, but a small number are periglomerular cells. In the adult SVZ, the primary neural stem cells are SVZ astrocytes rather than RGCs. Most of these adult neural stem cells lie dormant in the adult, but in response to certain signals, these dormant cells, or B cells, go through a series of stages, first producing proliferating cells, or C cells. The C cells then produce neuroblasts, or A cells, that will become neurons.[22]

Significant neurogenesis also occurs during adulthood in the hippocampus of many mammals, from rodents to some primates, although its existence in adult humans is debated.[23][24] The hippocampus plays a crucial role in the formation of new declarative memories, and it has been theorized that the reason human infants cannot form declarative memories is because they are still undergoing extensive neurogenesis in the hippocampus and their memory-generating circuits are immature.[25] Many environmental factors, such as exercise, stress, and antidepressants have been reported to change the rate of neurogenesis within the hippocampus of rodents.[26][27] Some evidence indicates postnatal neurogenesis in the human hippocampus decreases sharply in newborns for the first year or two after birth, dropping to "undetectable levels in adults."[28]

Neurogenesis has been best characterized in the fruit fly, Drosophila melanogaster.[29] In Drosophila, Notch signaling was first described, controlling a cell-to-cell signaling process called lateral inhibition, in which neurons are selectively generated from epithelial cells.[30][31] In some vertebrates, regenerative neurogenesis has also been shown to occur.[32]

Link:
Neurogenesis - Wikipedia

Personalized Medicine is defined as the customization of healthcare, where medical decisions are tailored to the individual patient based on their susceptibility to disease or response to a particular treatment. A key component of personalized medicine includes advanced testing of a patient's genetic information to help identify targeted treatment options.The practice of personalized medicine is based on the premise that for many diseases, including cancer, there is no one-size-fits-all treatment. In personalized medicine, diagnostic tests are used to help tailor disease prevention, diagnosis, and treatment based on the genetic makeup of a particular patient.1

At Abbott Molecular, we know that when patients and physicians are informed about the diagnostic and treatment opportunities offered by the promise of personalized medicine, lives can be saved. VisitRichard's Storyto learn about how personalized medicine has provided options and hope to patients and their families.

Companion Diagnostics (CDx) are laboratory tests developed in parallel with particular drugs to identify patients who are most likely to benefit from treatment with these drugs. Information from test results helps physicians to personalize patient treatment plans. Generally speaking, the practice of personalized medicine has been described as providing the right patient with the right drug at the right dose at the right time."1According to the Food and Drug Administration, personalized medicine may be considered as customizing medical treatment to the individual characteristics, needs, and preferences of a patient during all stages of care, including prevention, diagnosis, treatment, and follow-up.2

Many of the world's leading pharmaceutical, biological, and entrepreneurial companies select Abbott Molecular as their companion to develop comprehensive, companion diagnostic products and strategies.

There is no typical cancer patient. People diagnosed with cancer represent various races, ages, and lifestyles. Working with your physician to understand the causes, diagnosis, and treatment of cancer may help minimize concerns and is a positive first step in any fight against the disease. The following categories of frequently asked questions are provided for educational purposes only and are not intended to replace discussions with your healthcare provider.

1, 2http://www.fda.gov/ScienceResearch/SpecialTopics/PersonalizedMedicine/ucm20041021.htm. Accessed 3.25.14.

Read more here:
What is Personalized Medicine | Abbott Companion Diagnostics

Genetic testing

TheHuman Genome Projectled to the discovery of thousands of disease genes. Genetic testing can help patients determine disease risk and the likelihood of passing on or inheriting certain disorders.

Learn more aboutgenetic testingand how to use this information in your practice.

LINKS 1-6: Topics in genetics & personalized medicine

Genetic testing is expected to become a routine part of patient care in the future, but unless this DNA information is protected, the potential grows for discrimination against people based on their genetic information.

Understand more aboutgenetic discrimination.

LINKS 1-6: Topics in genetics & personalized medicine

Gene patentingis a broad term referring to the patenting of genetic sequences such as DNA and RNA, and to alternative forms of DNA such as cDNA (complementary DNA).

Learn more aboutgene patentingand its impact on patient care.

LINKS 1-6: Topics in genetics & personalized medicine

Direct-to-Consumer (DTC) genetic tests are marketed and sold directly to consumers, and do not require the assistance of a physician or other health care provider to obtain or interpret.

Learn aboutDTC genetic tests.

LINKS 1-6: Topics in genetics & personalized medicine

Precision medicine is a tailored approach to health care that accounts for the individual variability in the genes, environment and lifestyle of each person.

Learn more aboutprecision medicineand the President's Precision Medicine Initiative.

LINKS 1-6: Topics in genetics & personalized medicine

Go here to read the rest:
Selected topics in genetics & personalized medicine ...

Cancer Genomes

Cancer is a genetic disease. It starts with one unlucky cell that loses control over growth and division and evades the immune system; it continues with accumulation of mutations in the genome of its progeny that make them grow even faster; and it eventually reaches the point where it is detected by a physician. SCGPM researchers are devising new approaches to study genomic changes in cancers, to understand cancer origins and progression, and to determine which altered genes might be developed into drug targets.

The human brain has 100 billion neurons that govern how we think, feel, learn, and remember. Defects in the formation of these neurons during development can lead to mental retardation, and during aging or in diseases such as Alzheimer's, there is a decline in cognitive function, particularly memory. SCGPM scientists are identifying the molecular changes that occur in brain cells during development, aging, and diseases. Identifying these molecular changes will provide new avenues to ameliorate neurological diseases and to prevent age-dependent decline in cognitive function.

SCGPM scientists are investigating the genetic basis of Mendelian, oligogenic, and complex human cardiovascular diseases employing high-throughput sequencing of informative families and association-based whole genome scanning methodologies with large case-control cohorts. Causal genetic variation identified through these approaches is under investigation to elucidate the mechanistic basis for the disease associations.

See the article here:
SCGPM | Stanford Center for Genomics and Personalized ...

About Conference

Euro Personalized Medicine 2019Conference welcomes the Professors, Pathologists, Specialists,Clinical Geneticist, Cytogenetic Diagnostics, Therapists, Researchers Specialized from Molecular Genetics and Genomics, Physicians and Hospitalists with different specialties such as Endocrinologist, Cardiologist,Nephrologist, Orthopaedic, Haematologists, Immunologists,Oncologists, Rheumatologist, Research scholars, Industrial professionals and Student delegates from Biomedical, Pharmaceuticals and Telemedicine and Healthcare Sectors to be a part of it, from all over the world to Rome Italy . We are delighted to invite you all to attend and register at 10thEuropean Conference on Predictive Preventive and Personalized Medicine & Molecular Diagnostics " which is going to be held during August 29-30, 2019, in London UK.

The theme of the conference isExploring Innovations in advancing Personalized Medicine and Bio-Markers.Euro Personalized Medicine is a multidisciplinary field, interesting and interactive scientific sessions have been designed accordingly for this conference which includes the diagnosis, care and management of different acute and chronic medical conditions, comprises of various medical specialties such as cardiac health issues, brain disorders, digestive diseases, blood disorders, respiratory diseases, different types of cancers , immunological andinfectious diseases, basically all minor and major health issues which requires short and long-term, comprehensive care.

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Euro Personalized Medicine -2019, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Euro Personalized Medicine-2019 organizing committee look forward to meeting you in Euro Personalized Medicine -2019.

Conference Series Ltd has an enhanced and highlighted features of scientific partnerships and alliances with development agencies, Institutes, leading research organizations, non-government organizations, and other entities to promote the development-oriented research acrossthe globe through live streaming, B2B and Scientific Meetings. Conference Series LtdsMedical Conferencesprovides an excellent opportunity for the budding scientists and young researchers through its special initiatives like Young Researcher Forum, Poster Presentation and E-poster. Conference Series Ltd Organizes 300+Scientific Conferencesevery year across USA, Europe & Asia. Besides 500 Peer reviewed, Open Access Journals, Conference Series Ltd has collaborated with more than 1000Scientific Associationsand institutions worldwide to promote information on health care and technologies. These journals are enjoying the support of over 5 million readers; a team of 30.000 eminent scholars is providing editorial support.

Importance and scope:It estimated that 57 countries have an absolute shortage of 2.3 million physicians and nurses, midwives. This shortage of primary health care professionals suggests that many countries have insufficient numbers of health professionals to deliver essential health interventions. The shortage is defined as having a projected supply of primary physicians that meet less than 80% of the forecasted primary care demand or need, calculated at estimated means.

Who is Attending?

WHAT IS IT?

Preventive Medicine

Preventive healthcare consists of measures taken fordisease prevention, as opposed to disease treatment. Amedicineor other treatment designed to prevent disease or ill healths. Which is affected by environmental factors, genetic predisposition, disease agents, and lifestyle choices

Predictive Medicine

The branch of medical science or practice concerned with the prediction of the occurrence or course of disease in individual patients, now especially usinggeneticinformation.

Molecular diagnostics

Molecular diagnostics method used to analyzebiological markersin the genome and proteome and by applying molecular biology to medical testing. This technique is used to diagnose and monitor disease, detect risk, and decide which therapies will work best for individual patients.

Personalized medicine

Personalized medicineis amedicalpractice that separates patients into different groups withmedicaldecisions, practices, interventions, and products being tailored to the individual patient based on their predicted response andrisk of disease.

Personalized Medicinealludes as an individualized treatment which implies the solution of particular medications and therapeutics. Personalized Medicine 2019 highlights the topic"Exploring Innovations in advancing Personalized Medicine and Bio-Markers"alongside the logical system clears an approach to assembling visionaries through the exploration talks and presentations. A definitive mission of the meeting is to advance numerous interesting the Novel Approaches and Innovations in customized prescription and social insurance, serves a motivation for the progression ofMolecular Diagnostics, a brief talk on Protein Biomarkers, extraordinary spotlight onGeneticsInformed PersonalizedImmunotherapyandStem CellsTherapy as the Future of Personalized Medicine. Customized Medicine guarantees numerous restorative advancements, and can possibly change the way medications are found and utilized.

Conference Series Ltdis devotedly involved in conducting 300+Conference Series Ltd Every Year across Europe, USA (Baltimore, Chicago, Las Vegas, Philadelphia, and San Antonio) and almost all other parts of the world with support from 1000 more scientific societies and Publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Personalized medicine therapeuticsand companion diagnostic market have huge opportunities for growth in healthcare and will improve therapeutic effectiveness and reduce the severity of adverse effects approach todrug therapies. Personalized cancer medicine is self-made samples of translating cancer genetics into medical. There is a huge contribution ofGenomic medicineby revealing genomic variations; have an effect on health, sickness and drug response.Biomarkeralso plays vital role in the biological characteristic which can be molecular, anatomic, physiologic and chemical change drug development research which turns biomarkers intocompanion diagnostics.

Benefits of Attending the Conference

Supporting Journals:

Contact Person:

Andriana Samron

Program Manager | Euro Personalized medicine 2019

Phone:1-702-508-5200 x 8036

The 10thEuropeanConference onPredictive Preventive and Personalized Medicine & Molecular Diagnostics will be held on August 29-30, 2019 in London, UK will be organized around the themeExploring Innovations in advancing Personalized Medicine and Bio-Markerswhichcomprises 23 Sessions/Tracksto outline the theme of the conference organized byconference series llc LTDConferences. The main aim of the conference is to highlight the achievements and innovations in the various fields of Personalized Medicine across the globe.

Track 1:Molecular Diagnostics in Personalized Medicine

In personalized medicinemolecular diagnosticsis used for analysing of biological markers and also analysing by applying molecular biology to medical testing .This technique is used to diagnose and monitordisease, detect risk in individual patients .DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule .SNP genotyping is the measurement ofgeneticvariations of single nucleotide polymorphism (SNPs).which is the measurement of more generalgeneticvariation. Gene expression profiling is used for the measurement ofthe activity of thousands of genes at once.

Related Associations:

Alzheimers and Dementia Testing for Earlier Diagnosis

Association for Molecular Pathology Establishes New Standard for Clinical Utility of Molecular Diagnostics

British In Vitro Diagnostics Association (BIVDA)

California Life Sciences Association- Molecular Diagnostics

American Board of Clinical Chemistry

Molecular Diagnostics Laboratory

Association for Molecular pathology

Track2:Biomarkers Personalized Medicine

In personalized medicinebiomarkersand biological markergenerally refers to a measurableindicator of some biological state or condition. This wordrefers to a substance the presence of which indicates the existence of aliving organism. Biochemical biomarkers are often used inclinical trials, Biomarkers used forpersonalized medicineare typically categorized as either prognostic or predictive .In, a biomarkersis a molecule that allows the detection and isolation of a particular cell type. Abiomarkerindicates a change instate of a protein that correlates with the risk or progression of a disease . Biomarkers are useful in a number of ways, including measuring the progress ofdisease. Biomarkers also used inearlydiagnosis, disease prevention, drug target identification, drug response etc.

Related Associations:

ALS research Association

European society of cardiology

American Association of Pharmaceutical Scientists

American Board of Clinical Chemistry

Track3:Pharmacogenetic in Personalized Medicine

In personalized medicinepharmacogeneticsis the study of inherited genetic differences in drug metabolic pathways which can affect the drug responses, like therapeutic effect as well as adverse effect. Inter- and intra-individual variation ingene expressionand its function.In oncology,pharmacogeneticsrefers to germline mutations andpharmacogenomicsis study the somatic mutations in tumoral DNA leading to alteration in drug response

Related Associations:

European Society of Pharmacogenomics and Personalized Medicine

American Society of Human Genetics

Hungarian Society of Personalized Medicine

American Society for Investigative Pathology

Association for Molecular Pathology

Track4:Pharmacogenomics in Personalized Medicine

Pharmacogenomicsis the study of the role of genetics in drug response. It deals with the influence of acquired and inheritedgeneticvariation on drug response, drug absorption distribution, metabolism, and elimination ,as well as drug receptor target effects .Pharmacogenomicsis often used interchangeably with pharmacogenetics.Pharmacogenomics is used for the detection of the individualgeneticvariation with drug responsespharmacogeneticsfocuses on single drug-gene interactions, incorporatinggenomicsand epigenetics while dealing with the effects of multiplegeneson drug response

Related Associations:

Genetics societies

Canadian Association of genetics Counsellors

European Cytogeneticists Association

Human genome organization

International Genetic Epidemiology Society

British Society of Genetic Medicine

Track5:Pharmacoproteomics in Personalized Medicine

Theproteomeis the entire set ofproteinsit is expressed by genome , cell, tissue, or organism at a certain time. More specifically, it is a combined of proteins and genomes .Proteomicsis the study of the proteome. Acellularproteome is the collection of proteins present in a particularcelltype and it exposure to harmone stimulation . It can also be useful to consider an organisms complete proteome, which can be conceptualized as the complete set of proteins from all of the various cellularproteomes. Proteome used to refer to the collection of proteins in certain sub-cellularbiological systems.

Related Associations:

International precision medicine Associates

International Society of Personalized Medicine

British Society for Proteome Research

European Proteomics Association

Swiss Proteomics Society

Japan Society for clinical Proteomics

Track6:Metabolomics in Personalized Medicine

Metabolomicsis defined as the chemical processes involving of metabolites. Metabolomics is the study of the unique chemical fingerprints. Themetabolomerefers to the collection of all metabolites in a biological cell, tissue, organ or organism. mRNA gene expression data and proteomic analyses reveals the set of gene products in the cell. One of the challenges of system biology and functional genomics is to integrate proteomic ,transcriptomic, andmetabolomicinformation to provide acellular biology.

Related Associations:

Metabolomics Society

The Metabolomics Standards Initiative (MSI)

Metabolomics for a Low Carbon Society (METABOLOMICS)

Swiss Metabolomics Society

Metabolomics Research Group (MRG)

Track7:Personalized in Health Care

Personalized medicineis aMedical Practicethat separates patients into different groups with medical decisions, practices, interventions and products being tailored to the individual patient based on their predicted response or risk of disease. The words of personalized medicine,precision medicine,stratified medicineand P4 medicine are used interchangeably .

Related Associations:

American Health Care Association

Florida Health Care Association

OHCA Oregon Health Care Association

Texas Health care Association

Washington Health Care Association

Track8:Non- genomics Personalized Medicine

Epigenomicsis a set of epigenetic modifications on the genetic material of a cell is called as the epigenome. Epigenetics are reversible modifications on a cells DNA that affect the gene expression without altering the DNA sequence.Epigeneticmodifications are important role in the gene expressionand regulation, that are involved in the numerouscellularprocesses such as tumorigenesis.

Related Associations:

Genome Wide Association Studies (GWAS)

Genetics societies

Canadian Association of genetics Counsellors

European Cytogeneticists Association

Human genome organization

International Genetic Epidemiology Society

British Society of Genetic Medicine

German society of Human Genetics

Track9:Personalized Biological Therapies

Biological therapyrefers to the use of medication , specifically target an immune orgeneticmediator of disease. Even for diseases of unknown cause of molecules that are involved in the disease process have been identified, and can be targeted for biological therapy. which are mainly cytokines , are directly involved in the immune system .Biological therapyused for the management of cancer , autoimmune disease, and diseases of unknown cause that result in symptoms due to immune related mechanisms.

Read more here:
Euro Personalized Medicine Conferences 2019 | Molecular ...

Genomic medicine has long offered the promise of gene-based disease prevention and treatmentallowing medical providers to successfully predict, prevent, and treat disease based upon an individuals genetic or biomarker information. And while we are a long way from the fountain of youth, personalized medicine, also known as precision medicine, is no longer a future-situated hypothetical; many physicians even offer genetic testing at routine wellness visits. But personalized medicine triggers a host of questions for life sciences companies to sort through (i.e. manufacturing, commercializing, etc.), not the least of which pertain to quality and regulatory concerns.

While the practice of medicine has always been personalizedindividual patients treated based on their health profiles and disease markersthe evolving field of personalized and precision medicine involves more refined diagnostic testing than traditional medicine. And treatment is tailored to the patient after accounting for the patients unique biological, physiological, and environmental profiles. As defined by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), personalized medicine is the use of genetic or other molecular biomarker information to improve the safety, effectiveness, and health outcomes of patients via more efficiently targeted risk stratification, prevention, and tailored medication and treatment management approaches.

But given the departure from one-size-fits-all or trial and error diagnostic and treatment models, unique quality assurance challenges arise. For instance, how can adverse event tracking models apply to highly tailored treatments specific to each patients unique biology? How can clinicians and pathologists ensure that specimens remain valid and reliable throughout processing? And how will companies absolutely ensure the safety of protected health information that will increasingly include patients individual genetic code? These questions are generating a lot of buzz in the world of personalized and precision medicine and will continue to do so in the coming years.

Ironically, though the prevalence of adverse events theoretically decreases with the targeted provision of personalized medicine, a new problem of tracking adverse events emerges. While adverse event tracking in traditional medicine involves large sets of variable data, in personalized medicine, the number of variables is vastly increased.

Sophisticated big data analytics will continue to play an important role in adverse event detection, developing efficient flows of information and complex algorithmic solutions to assist pharmaceutical and biotech companies as well as regulators in successfully interacting with adverse event data.

A celebrated tenet of personalized medicine is that only treatments likely to benefit the patient are administered. But it was discovered that unreliable specimens led to inaccurate HER2 tests in up to 20 percent of cases, leading to inappropriate breast cancer treatment decisions. As a result, guidelines were established to ensure proper specimen-handling. However, such guidelines are not the norm vis--vis specimen processing and there is generally a lack of standardization as specimens travel from patient to pathologist.

As this issue becomes more visible, watch for further guidance from the following authorities: the American Society of Clinical Oncology (ASCO) as well as other professional organizations; the World Health Organization (WHO); the FDA; and the Centers for Medicare and Medicaid Services (CMS).

Another challenge for pharmaceutical and other life sciences companies is anticipating the regulations related to personalized healthcare, including gene and cell therapy. As human cell and gene therapy-related research and development rapidly expands, all stakeholders must watch for equally rapid shifts in regulations.

For the third year in a row, more than 25% of all new molecular entities (NMEs) approved by the FDAs Center for Drug Evaluation and Research (CDER) in 2016 were personalized medicines. And July 2017 saw the FDAs approval of Kymriah, Novartis CAR-T gene therapy, indicating the FDAs readiness to support personalized medicine. However, with novel biologic products comes minimal long-term evidence of safety and efficacy as well as a dearth of treatment experience. This doesnt help in alleviating uncertainty around the future of regulatory action and market viability of such personalized treatments.

Lately, many international workshops have convened to address the emerging regulatory issues pertaining to cell therapy while regulatory bodies have published guidance for cell therapy productsincluding several guidance documents added by the FDA in late 2017.

The well-known provision for real world evidence (RWE) in the recent 21st Century Cures Act (the Cures Act) has the potential for a major impact on the approvals of personalized medicine products. Given the non-traditional treatment profile of a gene therapy, RWE is especially helpful in assessing personalized medicines long-term benefits and risks in clinical practice. Under the sixth installment of the Prescription Drug User Fee Act (PDUFA VI), the FDA has committed to speeding the drug approval process by hiring more highly qualified experts as well as facilitating a more well-established use of real-world evidence to support post market drug safety surveillance by instating a new safety review system.

As with many emerging technologies, the enthusiasm surrounding personalized medicine is tempered by uncertainties in quality and regulatory schemas. As the shift to personalized medicine is younger than the laws that otherwise regulate the medical and research fields, there are frustrating gaps between technology and oversight. But these gaps should narrow while companies continue to make reasonable assumptions while they wait. As always, all stakeholders must remain vigilantly abreast of quality and regulatory developments as personalized medicine shows promise as the future of healthcare. Vigilance is of particular import to the many smaller developers of personalized medicines that may have limited resources or regulatory support.

Stakeholders must remember that regulatory views differ on a global basis, including between the FDA and the EMA. We expect a common set of principles to emerge as personalized medicine continues to secure its foothold as an accepted field of medical treatment.

If you found this information interesting, subscribe to our blog to receive the latest insights, like this one:

Excerpt from:
Personalized Medicine: Quality and Regulatory Issues

PhRMAs member companies are on the leading edge of personalized medicine development an area that is transforming health care, improving patient outcomes and creating health system efficiencies. In a new video, Dr. Bernie Zeiher, president of development of Astellas, discusses his excitement around the promise of personalized medicine, which uses diagnostic tools to help assess the medical treatments and procedures that may be best for each patient.

I am very optimistic about the future because the promise of personalized medicine has begun to be seen, Dr. Zeiher says in the video. Now, with more personalized-type therapies, you can test the tumor or test the blood to determine that in fact the person has a particular mutation, and then that will guide which therapy you would choose and it also increases the likelihood that the patient will respond.

Dr. Zeihers enthusiasm reflects the commitment of Americas biopharmaceutical companies to the development of these targeted treatments. Although there were only 13 FDA-approved personalized medicines in 2006, today there are more than 140. Additionally, personalized medicines accounted for more than 25 percent of FDA approvals last year, marking a record year for these innovative therapies.

Cancer is an area where personalized medicines are having a particularly big impact, driving tremendous advances for patients with highly aggressive cancers, like non-small cell lung cancer (NSCLC). In fact, research has shown nearly two-thirds of NSLCs have a genetic mutation that can be more effectively targeted with a personalized medicine.

Thanks to the hard work of biopharmaceutical researchers, like Dr. Zeiher, 42 percent of medications currently in the pipeline have the potential to be personalized. While the science has never been more complex, the future of research is bright with personalized medicine becoming a reality.

Read the rest here:
The Promise of Personalized Medicine | Innovation.org

Research can take a long time; therefore, we cannot guarantee that we will find information in your sample to return to you. As more samples are processed and genotyping is completed, the Biobank may find information that is medically important for some participants. This information is about genetic variations or changes in DNA that may affect how a person reacts to certain types of medications or that may increase risk of certain diseases, such as cancer or heart disease. For many of these diseases, there are medical options to reduce risk or manage the effects of disease.

If we learn something about your sample, such as information on your risk of certain diseases or health conditions, how you may respond to medications or your risk of being a carrier of certain diseases, we may be able to return this to you. We will ask your permission first before returning any information to you. However, not everyone will have this information, so we cannot guarantee that everyone will receive results

See original here:
Colorado Center for Personalized Medicine

Personalized medicine is gaining recognition due to limitations with standard diagnosis and treatment; many areas of medicine, from cancer to psychiatry, are moving towards tailored treatment for individual patients based on their genetic signatures and clinical characteristics. Advances in whole genome sequencing have allowed the identification of genes involved in a large number of diseases, and biomarkers that indicate disease severity or susceptibility to treatment are increasingly being characterized. The continued identification of new genes and biomarkers specific to disease subtypes and individual patients is essential for translation into personalized medicine, in terms of estimating both disease risk and response to therapy. This article collection covers recent advances in personalized medicine across all areas of medical science and clinical practice, demonstrating that patient-tailored treatment is being employed for some diseases, whereas more work is required to translate scientific advances into the clinic for others. We are seeking submissions of original research, reviews and debates offering insights into new advances in this exciting area of medicine.

Read the original:
Personalized medicine: genes, biomarkers and tailored treatment

Personalized medicine are drugs that are based on individual patient or intended patient groups carrying certain biomarkers and are created to cater the requirement of an individual patient based on the response produced by the patient suffering from a particular disease. The personalized medicines are currently in focus due to their effectiveness in cancer patients and patients suffering from rare genetic disorders. The fact that this approach could do away with the One Size Fits All approach leads to anticipations regarding higher treatment effectiveness through customization of prevention, prediction and treatments. In this regard, funds worth EUR 1 Bn has been invested by the EU as of 2015, focused on the development of personalized medicine, through its Seventh Framework Program for Research and Technological Innovation. The EU is also known to be coordinating with the member states on Health Technology Assessment for better understanding on cost-benefit-efficiency of including personalized medicines in their respective health systems. Constructive dialogue among global stakeholders could streamline the clinical trial processes and regulations regarding the same over the forthcoming years.

Personalized Medicine Market: Drivers & Restraints

Personalized medicine market is expected to witness rapid growth due to increasing disease incidence and deep focus of creating medicines for cancer patients where effectiveness has been proved to be higher as compared to other therapies. Rapid results & customized effects, lower probability of medication flaws and adverse drug reactions are some of the other factors that could create suitable traction in both R&D and revenue potential for these medicines. Favorable policies of the governments in relation to the personalized medicine will also add incremental opportunity to exploit this market. Recent developments in the pharmacogenomics are expected to create suitable environment for developing drugs, which are specific to one patient or group. Development of genetic databases could provide additional boost to the market. Upcoming therapeutic application opportunities in fields such as cardio-renal, neurology, antiviral, pulmonary, psychiatry among others could create R&D traction across all regions.

Complex nature of the drugs, high development costs, sub-optimal development framework and inter-patient variability of effects are some of the restraints that could hamper revenue growth of the personalized medicines market over the forthcoming years.

Personalized Medicine Market: Segmentation

This market can be segmented on the basis of Therapeutic area, End user and Application as follows:

Segmentation based on Therapeutic area

Oncology

Neurology

Cardiology

Antiviral

Psychiatry

Others

Segmentation based on End User

Hospitals

Molecular Diagnostic Laboratories and Testing facilities

Academic Institutes, clinical care and Research Laboratories

Contract Research Organizations

Bio and health informatics companies

Others (Service providers, partners, venture capitalists, etc.)

Segmentation based on Application

Companion Diagnostics

Biomarker identification

Health Informatics

Clinical Research

Personalized Medicine Market: Overview & Region wise Outlook

This market is mainly driven by increasing disease incidence of various cancers and other autoimmune diseases during the forecast period. The major growth in revenues is estimated to be contributed by markets in North America followed by Europe. This can be attributed to increasing pool of cancer patients along with high healthcare per capita expenditure. The ongoing research and legal initiatives in personalized medicine in Japan could promote the market growth in the country during the forecast period. In markets in Asia pacific and Latin America regions, accelerated development of R&D infrastructure could lead bigger drug makers to create their regional R&D centers focused on personalized medicine during the forecast period. The opening up research in the bioinformatics industry and active peer levels discussion and dialogues are factors that contribute to sustainable growth of the personalized medicines market in the medium to long term.

Personalized Medicine Market: Key Players

Some key players in this market are Roche Holding AG, Astra Zeneca PLC, Vertex Pharmaceuticals Inc., Qiagen Inc., BD (Becton Dickinson & Co., Merck & Co. Inc., Pfizer Inc., American Association for Cancer Research, Siemens Healthcare Diagnostics, Inc. among others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Regional analysis includes

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

APEJ (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE -All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Follow this link:
Personalized Medicine Market - Global Industry Analysis, Size ...

Stem cell therapy is a form of regenerative medicine that utilizes the bodys natural healing mechanism to treat various conditions.

Stem cells are being used in regenerative medicine to renew and repair diseased or damaged tissues, and have shown promising results in treatments of various orthopedic, cardiovascular, neuromuscular and autoimmune conditions.

Stem cells are present in all of us acting like a repair system for the body. However, with increased age sometimes the optimum amounts of stem cells are not delivered to the injured area. The goal of stem cell therapy is to amplify the natural repair system of the patients body.

There are two major types of stem cells embryonic stem cells and adult stem cells. Embryonic stem cells (ESCs) are stem cells derived from human embryos. They are pluripotent, which means they have the ability to develop into almost any of the various cell types of the body.

As the embryo develops and forms a baby, stem cells are distributed throughout the body where they reside in specific pockets of each tissue, such as the bone marrow and blood. As we age, these cells function to renew old and worn out tissue cells. These are called adult stem cells or somatic stem cells. Like embryonic stem cells, adult stem cells can also replicate into more than one cell type, but their replication is restricted to a limited number of cell types.

The unique self-regeneration and differentiating ability of embryonic stem cells can be used in regenerative medicine. These stem cells can be derived from eggs collected during IVF procedures with informed consent from the patient. However, many questions have been raised on the ethics of destroying a potential human life for the treatment of another.

Adult stem cells are most commonly obtained from the bone marrow, specifically the mesenchymal stem cells, which have the ability to replicate into cells that form the musculoskeletal system such as tendons, ligaments, and articular cartilage. They can be obtained from the iliac crest of the pelvic bone by inserting a needle and extracting the stem cells from the bone marrow.

Currently, stem cell therapy is used to treat various degenerative conditions of the shoulder, knees, hips, and spine. They are also being used in the treatment of various soft tissue (muscle, ligaments and tendons) as well as bone-related injuries.

You may be a good candidate for stem cell therapy if you have been suffering from joint pain and want to improve your quality of life while avoiding complications related to invasive surgical procedures.

The procedure begins with your doctor extracting stem cells from your own bone marrow. Bone marrow is usually aspirated from your hip region. Your doctor will first clean and numb your hip area. A needle is then introduced into an area of your pelvic bone known as the iliac crest. Bone marrow is then aspirated using a special syringe and the sample obtained is sent to the laboratory. In the laboratory, the aspirate is spun in a machine for 10 to 15 minutes and a concentrated stem cell sample is separated.

Your doctor then cleans and numbs your affected area to be treated and then, under the guidance of special x-rays, injects the stem cells into the diseased region. The whole procedure usually takes less than one hour and you may return home on the same day of the procedure.

The disadvantage of adult stem cell therapy is lack of data about its long-term effects as it is a newer evolving therapy.

Stem cell therapy is generally considered a safe procedure with minimal complications, however, as with any medical procedure, complications can occur.

Some risks factors related to stem cell therapy include infection as the stem cells may become contaminated with bacteria, viruses or other pathogens that may cause disease during the preparation process.

The procedure to either remove or inject the cells also has the risk of introducing an infection to the damaged tissue into which they are injected. Rarely, an immune reaction may occur from injected stem cells.

Read more:
Regenerative Medicine New York | Stem Cell Therapy

November 14 15, 2018 Harvard Medical School, Boston, MA

We need to make the transition to a predict, prevent and protect health system.

Joshua Ofman, M.D., M.S.H.S.Senior Vice President, Global Value, Access and Policy, Amgen

*** Speakers will be added to the schedule on a rolling basis as they are confirmed. ***

7:00 a.m.

Registration and Continental Breakfast

Joseph B. Martin Conference Center at Harvard Medical School77 Avenue Louis Pasteur, Boston, MA 02115

8:00 a.m.

Opening Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

8:10 a.m.

Setting the Stage: Exploring the Promise of Personalized Medicine A Keynote Address

SPEAKER | Elizabeth Nabel, M.D., President, Brigham and Womens Hospital

8:55 a.m.

Shifting Systems: Identifying the Common Challenges and Notable Achievements of Government Efforts to Advance Personalized Medicine

Government executives have an enormous influence over the direction of health systems and can therefore play a role in developing personalized medicine but they need to know what works and what doesnt if their respective efforts to promote personalized medicine are going to succeed. With that in mind, government representatives from around the globe will discuss the competitive advantages various countries have in personalized medicine and explore the common challenges and notable achievements of government initiatives to advance the field during this panel discussion.

MODERATOR | Antonio L. Andreu, M.D., Ph.D., Scientific Director, EATRIS European Infrastructure for Translational Medicine

Ora Dar, Ph.D., Senior Expert, Medical Sciences, consultant to the Israel Innovation Authority

Tom Fowler, Ph.D., Deputy Chief Scientist, Genomics England

Marc LePage, President, CEO, Genome Canada

Liisa-Maria Voipio-Pulkki, M.D., Ph.D., Director General, Chief Medical Officer, Ministry of Social Affairs and Health, Finland

10:10 a.m.

Networking Break

Light refreshments provided.

10:40 a.m.

Evaluating Patients Priorities: Understanding Perspectives on Personalized Medicine A Fireside Chat

MODERATOR | Susan McClure, Founder, Publisher, Genome magazine; Board Member, Personalized Medicine Coalition

Emily Kramer-Golinkoff, Co-Founder, Emilys Entourage, cystic fibrosis patient

Bryce Olson, Global Marketing Director, Health and Life Sciences Group, Intel Corporation; stage IV prostate cancer patient

11:10 a.m.

Automating Actionable: How Artificial Intelligence May Chart a Course for Personalized Medicine

Artificial intelligence may help inform personalized medicine in the future by perceiving which genes, proteins and other biological characteristics contribute to human disease. During this session, a diverse panel will discuss how artificial intelligence may accelerate drug development, improve clinical decision support and drive patient outcomes and what that might mean for the future of health care.

MODERATOR | Colin Hill, Chairman, CEO, Co-Founder, GNS Healthcare

Tom Miller, Managing Partner, GreyBird Ventures LLC

Gregg Talbert, Ph.D., Global Head of Digital and Personalized Health Care Partnering, Roche

Darrell M. West, Ph.D., Vice President of Governance Studies and Director of Center for Technology Innovation, Douglas Dillon Chair in Governance Studies, The Brookings Institution

1:40 p.m.

The Lay of the Lab: Exploring the State of the Clinical Laboratory Testing Industry A Keynote Address

SPEAKER | David King, J.D., Chairman, CEO, LabCorp

2:25 p.m.

The Diagnostics Discussion: Evaluating the Extent to Which the Regulatory and Reimbursement Environment for Diagnostic Tests May Help or Hinder Personalized Medicine

The U.S. Food and Drug Administration and the U.S. Centers for Medicare and Medicaid Services have been working for over a decade to develop regulatory and reimbursement pathways that promote the development of innovative diagnostic tests. Many observers, however, believe the current regulatory and reimbursement landscape still limits the field. This panel of business leaders will discuss the extent to which the existing frameworks and proposed policies may help or hinder personalized medicine.

MODERATOR | Joseph V. Ferrara, CEO, Boston Healthcare Associates

Michael Doherty, Senior Vice President, Head of Product Development, Head of Research & Development, Foundation Medicine

Julie Khani, President, American Clinical Laboratory Association

Kimberly Popovits, Chairman of the Board, CEO, President, Genomic Health

Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific

3:25 p.m.

Networking Break

Light refreshments provided.

Sponsored By

3:55 p.m.

Examining Policies: Exploring How Emerging U.S. Regulatory Approaches May Help Facilitate Personalized Care Regimens

The U.S. Food and Drug Administration (FDA) remains firmly committed to regulatory strategies designed to advance personalized medicine. During this wide-ranging fireside chat, two senior leaders from government and industry will discuss the agencys latest actions impacting the oversight of personalized medicine products and services. The discussion will cover topics including but not limited to next-generation sequencing, diagnostic test regulation, digital health, and real-world evidence.

MODERATOR | Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition

Jesse Berlin, Sc.D., Vice President and Global Head of Epidemiology, Johnson and Johnson

Lauren Silvis, J.D., Chief of Staff, Immediate Office of the Commissioner, FDA

4:55 p.m.

Engaging Everyone: Leveraging Diversity and Facilitating Equitable Access to Personalized Care

Advancing a medical paradigm that focuses on the unique characteristics of each patient will require, by definition, that patients from diverse backgrounds participate in the medical studies that advance our understanding of disease. Also critical is the need to ensure that those patients have access to personalized care informed by those studies. During this session, four panelists will discuss the effort to ensure that all patient populations benefit equally from personalized medicine.

MODERATOR | Donna R. Cryer, J.D., President, CEO, Global Liver Institute

Vence L. Bonham, Jr., J.D., Senior Advisor, Director on Genomics and Health Disparities, U.S. National Human Genome Research Institute

Alex J. Carlisle, Ph.D., Chairman, CEO, National Alliance Against Disparities in Patient Health

Adolph P. Falcn, Executive Vice President, National Alliance for Hispanic Health

Edward Tepporn, Executive Vice President, Asian & Pacific Islander American Health Forum

5:55 p.m.

Closing Remarks

SPEAKER | Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health

6:10 p.m.

Departure for the Museum of Fine Arts, Boston

6:30 p.m.

Welcome Reception at the Museum of Fine Arts, Boston

Avenue of the Arts465 Huntington AvenueBoston, MA 02115

Sponsored by

We will convene for cocktails and hors doeuvres at the Boston Museum of Fine Arts immediately after the first day of conference programming. The museum is in walking distance from the Conference Center.

Sponsored by

6:05 p.m.

Sponsored by

The successful implementation of [personalized medicine] will depend on the embrace of [its] principles in the business community.

Raju Kucherlapati, Ph.D.Paul C. Cabot Professor of Genetics, Harvard Medical School

*** Speakers will be added to the schedule on a rolling basis as they are confirmed. ***

7:00 a.m.

Registration and Continental Breakfast

Joseph B. Martin Conference Center at Harvard Medical School77 Avenue Louis Pasteur, Boston, MA 02115

8:00 a.m.

Opening Remarks

SPEAKER | Stephen L. Eck, M.D., Ph.D., Chief Medical Officer, Immatics U.S. Inc; Board Chair, Personalized Medicine Coalition

8:10 a.m.

Pioneering Precision: Inside the Pharmaceutical Industrys Push Toward Personalized Medicine A Fireside Chat

MODERATOR | Meg Tirrell, Reporter, CNBC

Daniel ODay, CEO, Roche Pharmaceuticals

8:55 a.m.

Considering Costs: Evaluating Emerging Pharmaceutical and Insurance Industry Business Models in Personalized Medicine

The pharmaceutical industry is deeply invested in commercializing personalized therapies that must recoup fixed development costs from smaller patient populations covered by health insurance companies that are increasingly concerned about rising health care costs. In that context, this diverse panel will explore the viability of the business model for developing and paying for personalized medicines, tackling issues related to costs, prices, and access.

MODERATOR | Meg Tirrell, Reporter, CNBC

Read more:
2018 Schedule 15th Annual Personalized Medicine Conference

NLM ID: 101574143Index Copernicus Value 2016: 84.15

Genetic Syndromes & Gene Therapy is an official peer-reviewed journal for the rapid publication of innovative research covering all aspects of Gene Mapping and Gene Therapy. Genetic Syndromes, Gene Mapping & Gene Therapy with highest impact factor offers Open Access option to meet the needs of authors and maximize article visibility and creates a platform for the authors to make their contribution towards the journal and the editorial office promises a peer review process for the submitted manuscripts for the quality of publishing.

Genetic Syndromes & Gene Therapy Journal is one of the best open access journals that aims to publish the most complete and reliable source of information on discoveries and current developments in the mode of original articles, review articles, case reports, short communications, etc. in the field and provide online access to the researchers worldwide without any restrictions or subscriptions.

Journal of Genetic Syndromes & Gene Therapy encompasses the continuous coverage of all biological and medical aspects of potential gene therapies for the birth defects along with genetic disorders which include treatments for cancers, arthritis, infectious diseases, inherited diseases like cystic fibrosis and Huntingtons disease, and also genetic abnormalities or deficiencies treated by incorporating specific engineered genes into the infected cells of patients body to people in electronic forms are immediately freely available to read download and share to improve the Open Access motto. The Journal of Genetic Syndromes & Gene Therapy provides reliable information updating online viewers with the modified methods and latest advancements in the field of gene therapy for diverse genetic disorders.

This Genetics journal is using Editorial Manager System for online manuscript submission, review and tracking. Editorial board members of the Genetic Syndromes & Gene Therapy or outside experts review manuscripts; at least two independent reviewers approval followed by editor approval is required for acceptance of any citable manuscript.

Environmental pollution is "the tainting of the physical and organic segments of the earth/air framework to such a degree, that ordinary natural procedures are antagonistically influenced.

Pollution is the introduction of pollutants into the environment that can cause harm or uneasiness to mankind or other living creatures and can also adversely affect usefulness of a resources of earth. Pollutants can be synthetic substances, or energy, for example: noise, heat or light.

Different types os Environmental pollution are:Air pollution, Water pollution, Noise pollution, Light pollution, Soil pollution, Radioactive pollution, Thermal pollution, Plastic pollution etc.

Down syndrome is one of the most common genetic disorder that affects both physical and mental ability. It is caused by a gene problem before birth.Generally a normal person posses 46 chromosomes but a person with Down Syndrome has 47 chromosomes.There are three different types of Down syndrome: trisomy, translocation, and mosaicism. Symptoms include short head,short neck,poor muscle tone, excessive flexibility etc.

Down Syndrome results when each cell in the body possess three copies of chromosome 21 instead of two copies. Extra copies of genes on chromosome 21 results in the disruption of normal function and development of the body which increases the risk of health problems. Down Syndrome occurs when part of chromosome gets attached to another chromosome during the formation of reproductive cells or embryo. Affected people possess two normal copies of chromosome 21 and one extra chromosome that is attatched to other.

Related Journals of Down Syndrome

Journal of Down Syndrome & Chromosome Abnormalities,Genetic Engineering, Stem Cell,American Journal of Medical Genetics, Down Syndrome Research and Practice,International Journal of Down Syndrome, International Medical Review on Down Syndrome, Down Syndrome Victoria, Journal of Intellectual Disability Research, Down syndrome Journals, Faseb Journal, Fetal Diagnosis and Therapy,Research paper on Down Syndrome,Latest Research on Down Syndrome

Genetic mutation is a permanent change in the DNA.Mutations may or may not produce changes in the organism.Hereditary mutations and Somatic mutations are the two types of Gene mutations.Former type is inherited from the parents and are present in every cell of the human body whereas latter type may occur at some point of life time due to environmental factors.

Certain enzymes repair gene mutations that could cause a genetic disorder. These enzymes identify and repair mistakes in DNA before the gene is expressed and an altered protein is produced. When a mutation alters a protein, it can disrupt normal development. Mutation may occur from a single DNA to a large segment of chromosome that involves multiple genes.

Related Journals of Genetic Mutations

Genetic Medicine, Genetic Engineering,Mutation Research/Genetic Toxicology and Environmental Mutagenesis, European Journal of Human Genetics, Genetics in Medicine, Human Mutation, Human Molecular Genetics, Genetic mutations Journals, Journal of Genetic Counseling,Genetic Journals, Genetic Disorder Articles,Journal of Genetic Mutation Disorders

Sickel cell anemia is a blood disorder caused by an abnormality in haemoglobin molecule in red blood cells.Person inherited by Sickle-cell disease has two abnormal copies of haemoglobin gene.Normal red blood cells are round and flexible whereas sickled red blood cells appear in sickle-shape.Abnormal haemoglobin forms strands that change red blood cells to that form and hence they accumulate at the branches of the veins and blocks the flow of blood.As haemoglobin is responsible for carrying of oxygen throught out the body,there may be chronic attacks due to lack of oxygen supply.

Mutations in HBB gene results in Sickle Cell disease. Haemoglobin consists of four subunits.Two subunits are Alpha-globin and other two are Beta-globin. HBB gene is responsible for making instructions in the production of Beta-globin. Hence mutations in HBB gene results in different abnormal versions of beta-globin.These abnormal versions may distort red blood cells into sickle shape.

Related Journals of Sickel Cell Anemia

Genetic Medicine, Genetic Engineering,Blood, American Journal of Epidemiology, American Society of Hematology, Journal of Clinical Pathology, Human Molecular Genetics, New England Journal of Medicine Science, Sickel cell anemia Journals

It is a type of disease that causes progressive weakness and loss of muscle mass. Here the process of mutation get involved in the production of proteins that are required to build a healthy muscle.Some types of Muscular dystrophy are Myotonic, Facioscapulohumeral , Congenital, Limb-girdle. It occurs when one of the genes responsible for production of proteins is defective.But some of them occur in the early stage of embryo and is passed to the next generation.

Duchenne Muscular Dystrophy is the most common form and mostly affect boys. It is caused due to the absence of dystrophin,a protein involved in maintining the integrity of muscle. Facioscapulohumeral Muscular Dystrophy generally begins at the teenage age and causes progressive weakness in muscles of face, arms, legs, shoulders and chest. Myotonic Muscular Dystrophy is the most common form and causes cataracts, cardiac abnormalities and endocrine substances.

Related Journals of Muscular Dystrophy

Carcinogenesis, Genetic Engineering,Journal of Medical Genetics, Molecular Therapy, Human Molecular Genetics, Human Genetics, American Journal of Human Genetics, PLOS Currents: Muscular Dystrophy, Muscular dystrophy Journals

Cystic fibrosis is a disorder caused by the presence of mutations in both the copies of the gene which is responsible for the protein cystic fibrosis transmembrane conductance regulator.It affects the cells that produce mucus, sweat and digestive juices.These fluids are thin and slippery but a defective gene causes these secretions to become thick ,thus blocking the passages in the lungs and pancreas.

Mutations in CFTR gene results in Cystic fibrosis. CFTR gene enables instructions for transportation of chloride ions into and out of the cells. Mutations in the CFTR gene disrupts the function of chloride channels that prevents the flow of chloride ions and water across cell membranes. As a result organs produce mucus that is thick and sticky which clogs the airways and ducts resulting isevere chronic attacks.

Related Journals of Cystic Fibrosis

Carcinogenesis, Genetic Engineering,Journal of Cystic Fibrosis, American Journal of Medical Genetics, European Journal of Human Genetics, American Journal of Human Genetics, American Journal of Respiratory and Critical Care Medicine, Journal of Genetic Counseling

An Auto immune disease develops when the immune system responsible for defending the body against diseases fights against the healthy cells. Here the immune system fails to differentiate healthy tissues and antigens, as a result the body sets off a reaction that destroy normal tissues.Some unknown trigger happens to confuse the immune system and instead of fighting against the infections it destroys the bodys own tissues.

Areas often affected by autoimmune disease include blood vessels, connective tissues, endocrine glands, joints, muscles, red blood cells, skin. Some common symptoms of autoimmune disease include fatigue, fever, joint pain, and rash. Some common autoimmune disorders include Addisons disease, Multiple Sclerosis, Type 1 diabetes, Sjogren syndrome, Reactive Arthritis, Dermatomyositis, Pernicious anemia, Celiac disease. This disorder may result in destruction of body tissue, abnormal growth of an organ, changes in organ function.

Related Journals of Auto immune Disease

Genetic Medicine, Genetic Engineering,Journal of Autoimmunity, Journal of Autoimmune Diseases, Journal of Autoimmune Diseases and Rheumatology, Open Journal of Rheumatology and Autoimmune Diseases, Advances in Immunology, International Immunology, Auto immune disease Journals

Mitochiondrial disease is a group of disorder caused by dysfunctional mitochondria. Mytochondria are responsible for generation of 90% of energy required by the body to sustain life and growth.These are also known as the power house of the cell.They contain tiny packages of enzymes that converts nutrients into energy. This disease is caused by mutations in mitochondrial DNA and its failure in function may ultimately lead to cell death.

Symptoms include loss of motor control, muscle weakness and pain,swallowing difficulties,liver disease,diabetes,cardiac disease,gastro-intestinal disorders and developmental delay.Ecamples on mitochondrial diseases include dementia,Diabetes mellitus and deafness,Leigh syndrome,neuropathy,Myoclonic epilepsy,strke-like symptoms,mtDNA deletion.

Related Journals of Mitochiondrial Disease

Genetic Engineering, Stem Cell, Mitochondrion, Disease and Molecular Medicine, International Review of Cytology-a Survey of Cell Biology, Journal of Inherited Metabolic Disease, Journal of Bioenergetics and Biomembranes, Molecular Genetics and Metabolism, Mitochiondrial disease Journals

Congenial syndromes is a disease that exists before birth.These are characterized by structural deformities and defects are involved in developing fetus.Defects may be due to genetic or environmental factors.The outcome of the disorder may be because of mothers diet, vitamin intake,glucose levels prior to ovulation. Paternal exposures prior to conception and during pregnancy increases the risk of this disease.It is caused by multiple mutations of the fibroblast growth factor receptor 2 gene.

Defects may include errors of morphogenesis,infection,epigenetic modifications or a chromosomal abnormality.The causes of this syndrome may be due to Fetal alcohol exposure,Toxic substances,Paternal smoking,Infections,Lack of nutrients,Physical restraint,Genetic causes,Socioeconomic status,Role of radiation,Fathers age.

Related Journals of Congenial Syndromes

Genetic Engineering, Stem Cell,Abdominal Imaging, Nature Genetics, Community Genetics, Faseb Journal, Mammalian Genome, Journal of Theoretical and Philosophical Psychology, Congunial syndromes Journals

Reye syndromes is a disease that causes swelling of the brainand liver .The actual cause is unknown but studies has shown that Aspirin is related to the cause of this disease generally in children and teenagers recovering from flu illness.The symptoms are vomiting, nausea, confusion,lethargy,coma, irritable and aggressive behavior.Abnormal laboratoty tests include rise in lever enzymes, ammonia levels and low serum glucose levels.

It is believed that tiny structures within the cell called the mitochondria become damaged. Mitochondria provide cells with energy to the liver for many of the vital functions such as filtering toxins from blood and regulating blood sugar levels. Failure of energy supply to the liver may result in build up of toxic chemicals in the blood which can damage the entire body.It is often seen in children ages 4 to 12. Symptoms are so mild that they go unnoticed. Early detection and treatment are critical but the chances for a successful recovery are greater when Reye Syndrome is treated at its earliest stages. Complications may include coma, permanent brain damage, seizures.

Related Journals of Reye Syndromes

Carcinogenesis, Genetic Engineering,Brain & Development, Annals of Neurology, Journal of Pediatric Gastroenterology & Nutrition, Brazilian Journal of Infectious Diseases, Archives of Disease in Childhood, Journal of The Neurological Sciences, Reye syndromes Journals

Patau syndromes is a disorder caused by chromosomal abnormality.It occurs when some or all the cells contain extra copy of the chromosome 13.This restricts the normal functioning ,growth and development of the organs resulting in intellectual disability and physical abnormalities. It is also called Trisomy 13.It also can occur when part of chromosome gets attatched to another chromosome during the formation of embryo.

Most cases of trisomy 13 are not inherited and results from the random events during the formation of eggs and sperm. An error in cell division may result in abnormal number of chromosome. If this extra copy contributes in the genetic makeup of child then the child possess an extra chromosome 13 in each cell of the body resulting in the physical abnormalities in most of the parts.

Related Journals of Patau Syndromes

Genetic Engineering, Stem Cell,Brain Research, Annals of Human Genetics, Prenatal Diagnosis, Clinical Dysmorphology, Fetal Diagnosis and Therapy, Journal of Intellectual Disability Research, Patau syndromes Journals

Fragile syndrome is a genetic disorder that results in intellectual disability.Mutations in the FMRI gene causes this disease. This gene is responsible for the preparation of a protein ,FMRP.This protein regulates the production of other proteins and is necessary for the development of synapses which are the connections between nerve cells.Mutations in FMRI prevents the production of FMRP ,thus disturbing the nervous system.

Males are severely affected by this disorder than females.Affected individuals usually have delayed development of speech and language by age 2.Children with fragile X syndrome may also have anxietyand hyperactive behavior such as impulsive actions. Fragile X syndrome is inherited in an X-linked dominant pattern. This condition is considered as X-linked since the mutated gene that causes the disorder is located on X chromosome.

Related Journals of Fragile Syndrome

Genetic Engineering, Stem Cell,Human Genetics, American Journal of Medical Genetics, Human Molecular Genetics, American Journal of Human Genetics, Nature Genetics, Journal of Medical Genetics, Fragile syndrome Journals

Angelman syndrome is a genetic disorder that affects the nervous system.Characteristic features include happy demeanor,intelluctual disability,speech impairment,walking and balancing disorders.This arises when segment of the maternal chromosome 15 containing the gene UBE3 A is deleted or undergoes mutation.People inherit one copy of this gene from each parent and both the copies remain active in many of the body tissues.But due to genetic mutations, gene may become active or get deleted in some parts of the brain resulting in intellectual disability.

Angelman Syndrome may also be caused by a chromosomal rearrangement called a translocation or by a mutation or other defect in the region of DNA that controls the activation of UBE3A gene. In some people with angelman syndrome the loss of a gene called OCA2 is associated with light colored hair and fair skin. This gene is located on the segment of chromosome 15 that is deleted in people with this disorder. Most cases of this syndrome are not inherited.

Related Journals of Angelman Syndrome

Carcinogenesis, Genetic Engineering,European Journal of Human Genetics, Brain & Development, Journal of Child Neurology, Cytogenetic and Genome Research, Neurobiology of Disease, American Journal on Mental Retardation, Angelman syndrome Journals

Tay-Sachs is a genetic disorder that destroys the nerve cells in the brain and spinal cord. Characteristic features include weakening of muscles,intellectual disability,vision and hearing loss,paralyses.Mutations in the HEXA gene causes this disease .This gene is responsible for the production of an enzyme in lysosome which plays a critical role in the brain and spinal cord.This enzyme breaks down the toxic substances in the cell.Mutations in the HEXA gene causes failure in the production of enzyme resulting in the accumulation of toxic substances in the cells leading to damage in the neurons of the brain and spinal cord.

Since Tay-Sachs disease impairs the function of a lysosomal enzyme this condition is sometimes referred to as a lysosomal storage disorder.This condition is inherited in which both the copies if the gene undergoes mutations. Persons with Tay- Sachs disease experience vision and hearing loss, intellectual disability and paralysis. An eye abnormality called a cherry-red spot is the characteristic feature of this disorder.

Related Journals of Tay-Sachs

Carcinogenesis, Genetic Engineering,Human Molecular Genetics, Sao Paulo Medical Journal, Journal of Neurochemistry, Journal of Molecular Biology, New England Journal of Medicine, Mammalian Genome - MAMM GENOME, Tay-Sachs Journals

Prenatal genetic testing is meant to evaluate the chance of exhibiting genetic disorders in their unborn children.The tests are usually done between 10th and 13th week of pregnancy . These tests involves the measurement of certain levels of substances in the mothers blood and obtaining an ultrasound.These tests are meant to evaluate the genetic material of the fetus for any genetic disorders.It is also useful to diagnose high risk pregnancies.

Genetic tests are performed on a sample of blood,hair,skin,amniotic fluid or other tissue.A positive test result means that the laboratory found a change in a particular gene, chromosome or a protein. A negative test result means that the laboratory did not find a change in the gene, chromosome or a protein that is under consideration.

Related Journals of Prenatal Genetic Testing

Carcinogenesis, Genetic Engineering,Obstetrics & Gynecology, Genetic Testing, Fetal Diagnosis and Therapy, Clinical Genetics, Prenatal Diagnosis, Journal of Midwifery & Womens Health, Prenatal genetic testing Journals,Genetic Testing Articles,Genetic Journals

Genes hold DNA that are responsible for giving instructions in the production of proteins.Mutations in genes may cause failure in the working of proteins leading to a condition called genetic disorder.These disorders may be inherited form parents or may occur at any point of lifetime.Genetic disorder may result in the addition or reduction in the number of chromosomes.

The four groups of genetic disorders are Single gene disorders, chromosome abnormalities, mitochondrial disorders, and multifactorial disorders. The four main ways of inheriting an altered gene are autosomal dominant, autosomal recessive, X-linked dominant and X-linked recessive. Genetic disorders may or may not be heritable. In non-heritable genetic disorders defects may be due to mutations in the DNA.

Related Journals of Genetic Disorders

Genetic Engineering, Stem Cell, Journal of Genetic Disorders & Genetic Reports, Journal of Medical Genetics, Journal of Genetic Mutation Disorders, Source Journal of Genetic Disorders, Genetic Disorders, Genes and Diseases, Genetic disorders Journals,Genetic Disorder Articles

Go here to see the original:
Journal of Genetic Syndromes & Gene Therapy

Color blindness (or colour blindness or more specific color vision deficiency (CVD)) is well known but hard to imagine if you are not suffering from it. So usually people are either looking for more information to learn about color blindness and all its details, would like to better understand the vision by simulating it or want to test themselves with some form of color blindness test. All this you can be found here on color-blindness.com and much more.

Color blindness affects approximately every 1 in 12 men (8%) and 1 in 200 women (0.5%). This means there is definitely one in your neighborhood or school class affected by it. Most of them are male, because the most common form called red-green color blindness (a term wich is also misleading) is encoded on the x-chromosome and therefore sex-linked. As red-green color blindness is inherited from a mother to her son, a father never passes this type of color blindness on to his children.

The term red-green color blindness is often used but actually not quite correct. Ever type of color vision deficiency affects the whole color spectrum and therefore can not be reduced to just certain colors. Of course, for the most often encountered types Protanomly (the milder form or red-weakness) or Protanopia (missing red cones, red-blindness) and Deuteranomaly (green-weakness) or Deuteranopia (green-blindness) the colors red and green are the most problematic and misinterpreted or indistinguishable ones. But people suffering from any of those forms have issues with the red or green part in every color, so the whole spectrum of colors is affected.

Besides red-green color blindness, which is encoded on the x-chromosome (sex-linked) and therefore much more common for men, there are also forms of color vision deficiency which are evenly distributed between male and female like Tritanomaly (blue-weakness) or Tritanopia (blue-blindness) and the real color blindness Achromatopsia (monochromacy) or the so called blue-cone monochromacy (only blue cones).

Color blindness simulation is fascinating! If you are not colorblind it is so hard to imagine what it looks like to be colorblind: Which color do you see? Do you see any at all? What does it mean not to be able to see red? and so on. My COlor BLIndness Simulator is a handy tool which allows you to use your own images and try out all the different simulation types. It is even possible to save any simulated image and have a one-by-one comparison.

Online color blindness testing is often done but unfortunately no yet as good as it could be. Usually youll find out about color blindness at school or when visiting an eye specialist and want to confirm this with some online tools. There are online color blindness tests available, but most of them are not reliable and cannot compensate a visit at your eye specialist. There is a new form of color blindness test coming up: Color Blind Check uses a new method and its results look very promising. But this new form still needs more time to develop and calibration to count as a trustable color blindness test.

View post:
Colblindor All about Color Blindness